D L Carlson Investment Group Inc. Sells 541 Shares of LivaNova PLC (NASDAQ:LIVN)

D L Carlson Investment Group Inc. lowered its position in shares of LivaNova PLC (NASDAQ:LIVN) by 2.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,483 shares of the company’s stock after selling 541 shares during the quarter. D L Carlson Investment Group Inc.’s holdings in LivaNova were worth $1,087,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Xponance Inc. raised its stake in shares of LivaNova by 6.1% during the fourth quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after buying an additional 445 shares during the last quarter. Swiss National Bank lifted its position in LivaNova by 0.7% in the 4th quarter. Swiss National Bank now owns 106,819 shares of the company’s stock valued at $4,947,000 after acquiring an additional 700 shares in the last quarter. Central Pacific Bank Trust Division boosted its position in shares of LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares during the period. Amalgamated Bank boosted its position in LivaNova by 3.0% during the fourth quarter. Amalgamated Bank now owns 24,900 shares of the company’s stock valued at $1,153,000 after purchasing an additional 729 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock valued at $8,240,000 after buying an additional 899 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Trading Down 1.2 %

LIVN stock opened at $39.13 on Monday. LivaNova PLC has a 52 week low of $36.85 and a 52 week high of $64.48. The company has a market capitalization of $2.13 billion, a PE ratio of 93.17 and a beta of 1.10. The company’s 50-day simple moving average is $44.51 and its 200 day simple moving average is $48.48. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Analyst Ratings Changes

A number of analysts have commented on the stock. Barclays cut their price target on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research note on Friday, March 7th. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 25th. Stifel Nicolaus dropped their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group reduced their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.